Acquisition Removes Friction from Complex Prior Authorizations to Benefit Patients, Clinicians, Providers, and Payers

此次收购消除了复杂事前授权流程中的摩擦，使患者、临床医生、医疗服务提供者和支付方受益

R1

R1

, an industry leader in healthcare revenue management, today announced that it has entered into an agreement to acquire

，作为医疗保健收入管理行业的领导者，今天宣布已达成协议收购

Humata Health

Humata 健康

(Humata), a leader in AI-powered, touchless prior authorizations. The transaction marks a significant step in advancing R1’s strategy to comprehensively automate the revenue cycle through its

（Humata），一家在基于人工智能的无接触预先授权领域处于领先地位的企业。此次交易标志着R1在通过其全面自动化收入周期战略方面迈出了重要一步

Phare Operating System

Phare 操作系统

(Phare OS), expanding the platform’s AI-powered capabilities while helping providers reduce administrative complexity, increase reimbursement accuracy, and improve financial outcomes.

（Phare OS），在扩展平台人工智能驱动功能的同时，帮助医疗服务提供者降低管理复杂性、提高报销准确性并改善财务成效。

Prior authorizations are a top-three driver of denials and a frequent source of frustration for health systems, clinicians, and patients. A recent

事先授权是导致理赔拒付的三大主要原因之一，也是医疗系统、临床医生和患者经常感到沮丧的根源。近期一项

KFF survey

KFF调查

found that one-third of insured adults identified prior authorization as the biggest burden faced when accessing healthcare, particularly for individuals with chronic health conditions. Staying up to date on frequently changing prior authorization policies is challenging, and securing authorizations typically requires significant manual effort for healthcare providers and payers..

研究发现，三分之一的有保险成年人将事先授权视为获得医疗服务时面临的最大负担，对于患有慢性健康疾病的个体而言尤其如此。随时掌握频繁变化的事先授权政策具有挑战性，而获得授权通常需要医疗服务提供者和支付方投入大量的人工努力。

R1’s Phare OS is a comprehensive automation platform that prioritizes pre-bill workflows for authorization, utilization review, documentation, and coding. It utilizes an AI-first architecture to prevent downstream denials and optimize reimbursement before claims are submitted. Humata’s authorization policy monitoring and agentic capabilities for autonomously creating effective authorization submissions will directly enhance Phare Intelligence and Payer Atlas, the foundation of Phare OS.

R1 的 Phare OS 是一个全面的自动化平台，专注于授权、使用审查、文档记录和编码等账单生成前的工作流程。它采用以人工智能为先的架构，在提交索赔之前防止后续拒付并优化报销。Humata 的授权政策监控功能以及自主创建有效授权提交材料的智能体能力，将直接增强 Phare Intelligence 和 Payer Atlas，这两者是 Phare OS 的基础。

Phare OS customers will also benefit from the ability to deploy additional modules, including Audit and Denials, with minimal incremental data integration. In addition, this strengthens the ability for Phare OS to support deeper collaboration between payers and providers, moving the industry closer to real-time authorizations..

Phare OS 客户还将受益于能够以最小的增量数据集成部署额外模块，包括审计和拒付模块。此外，这增强了 Phare OS 支持支付方与提供方之间更深入协作的能力，推动行业向实时授权迈进。

Humata Health is a leading health tech company dedicated to making prior authorization seamless for health systems, payers, and the patients they serve. With agentic workflows that intelligently match policies and connect to payers in real-time, its proprietary, end-to-end solution simplifies and accelerates every step of the medical review process.

Humata Health 是一家领先的健康科技公司，致力于为医疗系统、支付方及其服务的患者提供无缝的事前授权体验。通过能够智能匹配政策并实时连接支付方的代理工作流，其专有的端到端解决方案简化并加速了医疗审核流程的每一个步骤。

It determines requirement logic, creates AI-driven clinical bundles, provides evidence for payer attestations, and manages requests through final approval across all specialties. Humata’s solution allows providers to achieve up to a 96% first-pass approval rate while reducing write-offs by 30%, rescheduled appointments by 83%, and staff touches by 45%, delivering lower costs and friction for payers and providers, while ensuring patients gain faster access to care..

它确定需求逻辑，创建人工智能驱动的临床组合，为支付方证明提供证据，并管理所有专科的请求直至最终批准。Humata的解决方案使提供者能够实现高达96%的首次通过率，同时将注销减少30%，重新安排的预约减少83%，员工处理次数减少45%，从而降低支付方和提供方的成本和摩擦，同时确保患者能够更快地获得护理。

Following the closing of the transaction, expected to occur by the end of the third quarter, the Humata team will enhance R1’s

在预计于第三季度末完成的交易结束后，Humata 团队将增强 R1 的

R37 innovation lab

R37创新实验室

, R1’s agentic AI development team. R1 plans to connect Humata’s technology to Phare OS, accelerating AI-powered automation across the revenue cycle and supporting Humata’s ability to scale and serve its growing pipeline.

，R1 的智能体 AI 开发团队。R1 计划将 Humata 的技术与 Phare OS 相连接，加速贯穿收入周期的 AI 驱动自动化，并支持 Humata 扩大规模以服务其不断增长的客户管线。

“Today’s announcement marks an important step forward in our journey to automate the revenue cycle and make real-time authorizations a near-term reality,” said Joe Flanagan, Chief Executive Officer at R1. “Humata significantly enhances our coverage of the authorization process, advancing our strategy to have the most intelligent and integrated pre-bill architecture in the industry.

“今天的公告标志着我们在自动化收入周期并使实时授权在短期内成为现实的过程中迈出了重要的一步，”R1 首席执行官乔·弗拉纳根表示。“Humata 显著增强了我们对授权流程的覆盖范围，推动了我们的战略，即打造行业内最智能、最集成的预账单架构。”

Together, we will continue to shape the future of revenue cycle management and help deliver better outcomes for the patients, providers, and health systems we serve.”.

我们将携手继续塑造收入周期管理的未来，为我们服务的患者、提供者和医疗系统带来更好的成果。

“As a physician, I’ve seen firsthand how prior authorization delays drain providers and push an already strained healthcare system to a breaking point,” said Jeremy Friese, MD, Founder and CEO at Humata Health. “Fixing this broken process is urgent. By joining forces with R1 and its visionary R37 innovation lab, we can bring our prior authorization capabilities into the Phare OS platform, combining advanced AI and upstream intelligence with downstream execution to finally eliminate administrative friction for providers, payers, and patients.”.

“作为一名医生，我亲眼目睹了事前授权延误如何耗尽医疗服务提供者的精力，并将本已不堪重负的医疗体系推向崩溃边缘，”Humata Health 创始人兼首席执行官 Jeremy Friese 医学博士表示。“修复这一破损的流程刻不容缓。通过与 R1 及其具有前瞻性的 R37 创新实验室携手合作，我们可以将我们的事前授权能力融入 Phare OS 平台，将先进的人工智能和上游智能与下游执行相结合，最终消除医疗服务提供者、支付方和患者面临的行政摩擦。”

About R1

关于 R1

R1 is a leader in healthcare revenue management, helping providers achieve new levels of performance through smart orchestration. A pioneer in the industry, R1 created the first Healthcare Revenue Operating System: a modular, intelligent platform that integrates automation, AI, and human expertise to strengthen the entire revenue cycle.

R1 是医疗收入管理领域的领导者，通过智能协同帮助医疗服务提供者实现全新的绩效水平。作为行业先驱，R1 创建了首个医疗收入操作系统：这是一个模块化、智能化的平台，整合了自动化、人工智能和人类专业知识，以强化整个收入周期。

With more than 20 years of experience, R1 partners with 1,000 providers, including 95 of the top 100 U.S. health systems, and handles over 600 million payer transactions annually. This scale provides unmatched operational insight to help healthcare organizations unlock greater long-term value. To learn more, visit .

凭借二十余年的经验，R1 与 1,000 家提供商合作，其中包括美国前 100 大健康系统中的 95 家，每年处理超过 6 亿笔支付方交易。这一规模提供了无与伦比的运营洞察，帮助医疗机构释放更大的长期价值。欲了解更多信息，请访问 。

r1rcm.com

r1rcm.com

.

。

About Humata Health

关于 Humata Health

Humata Health

Humata Health

is a leader in AI-powered, touchless prior authorizations. A health tech company “Built for Yes,” its mission is to make prior authorization easy and seamless for providers, payers, and the patients they serve. With the industry’s largest ecosystem of integrations and proprietary technology that gathers the right clinical information required for fast approval, the Humata platform is the only truly end-to-end prior authorization solution for all services and procedures.

是人工智能驱动、无接触式事前授权领域的领导者。作为一家“为肯定而建”的健康科技公司，其使命是让医疗服务提供者、支付方及其服务的患者能够轻松、无缝地完成事前授权。凭借行业内规模最大的集成生态系统，以及专有技术可快速收集审批所需的关键临床信息，Humata 平台是唯一真正面向所有服务和诊疗流程的端到端事前授权解决方案。

Humata is a physician-led company that is backed by a syndicate of strategic healthcare investors including Blue Venture Fund, Sandbox Clinical Venture Fund, LRVHealth, .406 Ventures, and Highmark Ventures. Lazard served as exclusive financial advisor to Humata for this transaction..

Humata 是一家由医生领导的公司，获得包括 Blue Venture Fund、Sandbox Clinical Venture Fund、LRVHealth、.406 Ventures 和 Highmark Ventures 在内的战略医疗健康投资者财团的支持。Lazard 担任 Humata 在此次交易中的独家财务顾问。

Originally announced August 18th, 2026

最初于2026年8月18日宣布

Get Fresh Healthcare & IT Stories Delivered Daily

每日获取最新的医疗与IT资讯

Join thousands of your healthcare & HealthIT peers who subscribe to our daily newsletter.

加入成千上万的医疗和HealthIT同行，订阅我们的每日通讯。

We respect your privacy and will never sell or give out your contact information

我们尊重您的隐私，绝不会出售或泄露您的联系方式。